Key Highlights
- Kodiak Sciences (NASDAQ: KOD) surged after positive Phase 3 DAYBREAK data for Zenkuda and KSI-501 in wet AMD.
- ClearOne (NASDAQ: CLRO) extended a speculative move tied to its pending Cortigent Merger and thin trading float.
- Lakewood-Amedex (NASDAQ: LABT) attracted attention around Nu-3 clinical progress and recent antimicrobial data.
- Accuray (NASDAQ: ARAY) announced a volumetric-imaging collaboration with Samsung NeuroLogica for CyberKnife.
- Game Your Game (NASDAQ: GYGY) moved after its GameGolf KZN AI platform reached full commercial availability.
- Volato Group (NYSE American: SOAR) remained in focus following its completed Alignment Engine merger and planned AI-infrastructure expansion.
Pre-Market Movers: Company-Specific Catalysts Take Centre Stage
The US pre-market session on September 28 was dominated less by broad macroeconomic themes and more by individual corporate catalysts.
Clinical-trial results, merger developments, new product launches, strategic partnerships and AI-infrastructure plans were behind some of the sharpest moves. The effect was amplified in several cases by relatively small floats and unusually high trading volumes.
Data from a pre-market movers tracker showed Game Your Game (NASDAQ: GYGY) up as much as 93% and ClearOne (NASDAQ: CLRO) up roughly 80% during the morning session, with CLRO showing exceptionally high relative volume.
Here are the key names investors were watching.
Kodiak Sciences (NASDAQ: KOD): Phase 3 Data Changes the Story
Kodiak Sciences became one of the session's most closely watched biotech names after reporting that Zenkuda (tarcocimab tedromer) and KSI-501 (tabirafusp alfa tedromer) met their primary endpoints in the pivotal Phase 3 DAYBREAK study evaluating treatments for wet age-related macular degeneration.
The DAYBREAK trial compared the investigational therapies against aflibercept, with the primary objective centred on non-inferiority in visual-acuity outcomes. Kodiak had previously said the trial was designed around a treat-to-dryness approach and flexible dosing intervals for Zenkuda.
The latest results provide an important clinical catalyst because Kodiak is a pre-commercial biotechnology company whose valuation is closely tied to its late-stage pipeline.
The company has also been preparing for potential regulatory filings for Zenkuda. Its earlier disclosures highlighted Zenkuda's potential for longer dosing intervals and the company's proprietary antibody-biopolymer conjugate platform.
The significance for investors is therefore broader than a single trial result: the readout provides another data point on whether Kodiak's technology can support a differentiated retinal-treatment franchise.
ClearOne (NASDAQ: CLRO): Merger Speculation Meets a Thin Float
ClearOne was another major pre-market mover, although its catalyst was different.
Unlike Kodiak, there was no fresh clinical readout driving the September 28 move. Instead, trading appeared to extend recent interest surrounding ClearOne's proposed combination with Cortigent, a Subsidiary of Vivani Medical.
Under the previously announced transaction, Cortigent would become a Wholly Owned Subsidiary of ClearOne. ClearOne also agreed to pursue a concurrent financing of between $10 million and $15 million in connection with the transaction.
Vivani subsequently disclosed that it anticipated the pricing and closing of the transaction in October 2026.
That timeline gives traders a near-term corporate event to monitor.
The stock's reaction was also magnified by its trading characteristics. Pre-market data showed CLRO with extremely high relative volume, illustrating how quickly buying pressure can move a thinly traded security.
Lakewood-Amedex (NASDAQ: LABT): Nu-3 Clinical Catalyst
Lakewood-Amedex continued to attract attention after a series of developments surrounding Nu-3, its lead antimicrobial candidate for infected diabetic foot ulcers.
On September 24, the company announced that the first patient had been dosed in a Phase 2a clinical trial. The study is evaluating three concentrations of Nu-3 and is designed to assess safety and efficacy while helping determine dosing for subsequent development. Topline data are expected in the first quarter of 2027.
The catalyst follows earlier regulatory and clinical preparations. Lakewood-Amedex announced on September 18 that it had obtained central and site-level IRB approvals and confirmed clinical-site readiness for the Phase 2a trial.
The company has also highlighted preclinical data suggesting broad antimicrobial activity and a differentiated resistance profile for its Bisphosphocin platform. Those findings remain preclinical and therefore do not establish clinical efficacy, but they provide context for why investors are watching the Phase 2 program.
For LABT, the next major question is whether clinical data can validate the technology beyond laboratory and preclinical evidence.
Accuray (NASDAQ: ARAY): Samsung Partnership Adds a Technology Catalyst
Accuray entered the spotlight after announcing agreements with Samsung NeuroLogica to pursue advanced volumetric imaging capabilities for the CyberKnife platform.
The collaboration, announced ahead of the ASTRO Annual Meeting, combines Samsung NeuroLogica's expertise in mobile CT and volumetric imaging with Accuray's robotic radiosurgery, precision-treatment delivery and motion-management technology.
The companies are targeting imaging capabilities that could provide clinicians with additional information closer to treatment decisions.
For Accuray, the development is less about an immediate Revenue event and more about expanding the technological capabilities of its CyberKnife platform.
That distinction matters. Partnerships can create strategic optionality, but the commercial impact depends on development, implementation, customer adoption and eventual deployment.
Game Your Game (NASDAQ: GYGY): From Limited Release to Commercial Launch
Game Your Game delivered a different type of catalyst: commercialization.
The company announced that its GameGolf KZN AI platform had moved from limited release to full commercial availability. The product combines golf-shot tracking, GPS and AI-driven analytics and is now available for purchase through the company's website.
The company describes the platform as using club-mounted sensors, GPS and AI analytics to provide golfers with automated shot tracking and performance insights.
The September 23 announcement means the September 28 move was not necessarily driven by a new product announcement that morning. Instead, the market was continuing to digest the transition from development and limited release toward commercial sales.
The stock's trading profile added another layer to the move. Pre-market data showed GYGY up sharply with Volume running at more than 1,000 times its recent level on the relevant tracker.
That combination of a commercialization milestone and extreme volume can create unusually large price swings in a small-cap security.
Volato Group (NYSE American: SOAR): AI Infrastructure Enters the Picture
Volato's story is tied to the broader AI-infrastructure Investment cycle.
The company completed its previously announced merger with Alignment Engine, transforming the strategic direction of the Business toward AI infrastructure, high-density computing and data-center development. The combined company has an Ohio site with power, water and water-treatment infrastructure already operational.
The transaction originally valued Alignment Engine at approximately $500 million and provided Volato with a platform targeting up to 480 MW of capacity, with 154 MW available at the time of the original merger announcement.
Alignment Engine's infrastructure is designed for high-performance GPU computing, AI training, inference and other compute-intensive workloads.
The broader significance is the growing intersection between AI Demand and physical infrastructure. Power availability, data-center capacity, GPUs and financing have become increasingly important constraints as companies expand AI workloads.
For SOAR, however, the opportunity also comes with execution requirements. The company has said its near-term focus includes equipment, financing, procurement and customer deployments.
Why These Stocks Are Moving So Fast
The common thread across these six names is catalyst intensity.
KOD has a late-stage clinical readout.
CLRO has a pending corporate transaction.
LABT is advancing a clinical-stage drug.
ARAY has a technology partnership.
GYGY has moved into full commercial availability.
SOAR is repositioning around AI infrastructure.
But there is another common factor: trading liquidity.
When a company has a relatively small freely traded share base, a sudden increase in volume can produce disproportionately large price movements. That is particularly visible in pre-market trading, where Liquidity is typically thinner than during regular market hours.
This does not necessarily mean that the underlying businesses have changed by the same percentage as their share prices.
Instead, the pre-market session is often the market's first attempt to establish a new price around a fresh catalyst.
The Bottom Line
September 28's pre-market action illustrates the different ways a small-cap stock can suddenly enter the market's spotlight.
For biotech companies such as KOD and LABT, the catalyst is clinical progress. For CLRO, it is a pending transaction. ARAY is being driven by a technology collaboration, while GYGY is moving from product development toward commercial availability. SOAR represents the increasingly crowded intersection between AI demand, power and data-center infrastructure.
The key distinction for investors is between a headline catalyst and a durable business change.
Clinical data still have to translate into regulatory and commercial outcomes. Partnerships must become products or revenue. Product launches must generate sales. Mergers must close and integration must follow. AI-infrastructure plans ultimately require capital, power, equipment and customers.
That is why the biggest pre-market percentage move is not necessarily the biggest fundamental development.
On September 28, the market was pricing the catalysts first. The next phase will be determining which of them can translate into measurable business results.





_11_20_2026_12_38_15_908731.jpg)
Please wait processing your request...